NR1H4 and metabolic dysfunction-associated steatohepatitis: Hepatic FXR activation in NASH exerts systemic effects that include the upregulation of fatty acid oxidation, inhibition of de novo lipogenesis and fatty acid synthesis via SHP-mediated suppression of SREBP-1c, and decreased gluconeogenesis, thereby mitigating IR.